Explore the latest updates in the treatment of Alzheimer's disease (AD) Different therapeutic strategies against β-amyloid (Aβ) 
plaque formation, one of the main histopathological hallmarks of AD, have been tested in randomized controlled trials (RCTs) in recent decades. Monoclonal antibodies (mAbs) that reduce Aβ in the brain are the most promising treatment strategies today.